MicroRNA signatures in malignant pleural mesothelioma effusions

K.A. Birnie; C.M. Prêle; A.W. Musk; N. de Klerk; Y.C.G. Lee; D. Fitzgerald; R.J.N. Allcock; P.J. Thompson; J. Creaney; B. Badrian; S.E. Mutsaers

doi:10.1155/2019/8628612

Back

MicroRNA signatures in malignant pleural mesothelioma effusions

Journal article

Open access

Peer reviewed

MicroRNA signatures in malignant pleural mesothelioma effusions

K.A. Birnie, C.M. Prêle, A.W. Musk, N. de Klerk, Y.C.G. Lee, D. Fitzgerald, R.J.N. Allcock, P.J. Thompson, J. Creaney, B. Badrian, …

Disease Markers, Vol.2019, pp.1-9

2019

DOI: https://doi.org/10.1155/2019/8628612

Files and links (2)

pdf

MicroRNA.pdfDownload View

Published (Version of Record) Open Access

url

Free to Read *No subscription requiredView

Abstract

Malignant pleural mesothelioma (MPM) is an incurable cancer of the pleura that can be difficult to diagnose. Biomarkers for an easier and/or earlier diagnosis are needed. Approximately 90% of MPM patients develop a pleural effusion (PE). PEs are ideal sources of biomarkers as the fluid would almost always require drainage for diagnostic and/or therapeutic reasons. However, differentiating MPM PE from PE caused by other diseases can be challenging. MicroRNAs are popular biomarkers given their stable expression in tissue and fluid. MicroRNAs have been analysed in PE cytology samples for the diagnosis of MPM but have not been measured in frozen/fresh PE. We hypothesise that microRNAs expressed in PE are biomarkers for MPM. TaqMan OpenArray was used to analyse over 700 microRNAs in PE cells and supernatants from 26 MPMs and 21 other PE-causing diseases. In PE cells, combining miR-143, miR-210, and miR-200c could differentiate MPM with an area under the curve (AUC) of 0.92. The three-microRNA signature could also discriminate MPM from a further 40 adenocarcinomas with an AUC of 0.9887. These results suggest that the expression of miR-143, miR-210, and miR-200c in PE cells might provide a signature for diagnosing MPM.

Details

Title: MicroRNA signatures in malignant pleural mesothelioma effusions
Authors/Creators: K.A. Birnie (Author/Creator) - Institute for Respiratory Health
C.M. Prêle (Author/Creator) - Harry Perkins Institute of Medical Research
A.W. Musk (Author/Creator) - Sir Charles Gairdner Hospital
N. de Klerk (Author/Creator) - The Kids Research Institute Australia
Y.C.G. Lee (Author/Creator) - Sir Charles Gairdner Hospital
D. Fitzgerald (Author/Creator) - Sir Charles Gairdner Hospital
R.J.N. Allcock (Author/Creator) - Pathwest Laboratory Medicine
P.J. Thompson (Author/Creator) - Institute for Respiratory Health
J. Creaney (Author/Creator) - Sir Charles Gairdner Hospital
B. Badrian (Author/Creator) - Institute for Respiratory Health
S.E. Mutsaers (Author/Creator) - Harry Perkins Institute of Medical Research
Publication Details: Disease Markers, Vol.2019, pp.1-9
Publisher: Hindawi Publishing
Identifiers: 991005541157507891
Copyright: © 2019 Kimberly A. Birnie et al.
Murdoch Affiliation: Murdoch University
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

10 File views/ downloads

30 Record Views

24 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.297 Asbestos & Mesothelioma; 1.297.780 Asbestos-Mesothelioma Link
Web Of Science research areas: Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology
ESI research areas: Clinical Medicine